CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-488

Apologies, I found the full year 2023 stuff which has not been posted here in HC, along with a lot of other stuff missing, which is strange:

In 2022 EYE had revenues (sales/gross income) of $13.378 mil and a net loss of $7.817 - expenses of $21.195 mil.

In 2023 EYE had revenue of $17 mil and a loss of $17 mil, so expenses of $34 mil, of which there was $6.044 mil recorded as a one off impairment, obviously with normalised expenses of $28 mil.

In 2024 income has been $23.5 mil, so it remains to be seen how much expenses have risen. They are expected to have risen substantially and there will be a significant loss.

*The impairment item was due to the inability of the AlphaRET segment to generate independent cashflows, requiring a cash investment of $6.044 mil, more than the company had available. Not quite a one off non cash item as characterised by TheAnalyst007